No margin for non-adherence: Probabilistic kaplan-meier modeling of imatinib non-adherence and treatment response in CML (ADAGIO study)-Reference-Cited by-同舟云学术

No margin for non-adherence: Probabilistic kaplan-meier modeling of imatinib non-adherence and treatment response in CML (ADAGIO study)

Published:2021-12 Issue: Volume:111 Page:106734
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Obeng-Kusi Mavis,MacDonald Karen,van Lierde Marie-Anne,Lee Christopher S.,De Geest Sabina,Abraham Ivo

Funder

Novartis

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference15 articles.

1. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study;Noens;Blood,2009

2. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib;Marin;J. Clin. Oncol.,2010

3. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet;Baccarani;Blood,2006

4. Analysis of imatinib adherence in chronic myeloid leukemia: a retrospective study in a referral hospital in the Brazilian Amazon;Andrade;Hematol Transfus Cell Ther.,2019

5. Prevalence and determinants of non-adherence to Imatinib in the first 3-months treatment among newly diagnosed Ethiopian’s with chronic myeloid leukemia;Fentie;PLoS One,2019

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness of mHealth apps on adherence and symptoms to oral anticancer medications: a systematic review and meta-analysis;Supportive Care in Cancer;2024-06-12

2. Patient Versus Physician Perspective in the Management of Chronic Myeloid Leukemia During Treatment with Tyrosine Kinase Inhibitors;Oncology and Therapy;2023-12-16

3. Patient‐reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemia;Cancer;2023-10-06

4. Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel Insights;Cells;2023-06-23

5. Volumetric dried blood microsampling for monitoring imatinib mesylate therapy: Method development and clinical application in patients with chronic myeloid leukemia;Journal of Pharmaceutical and Biomedical Analysis;2023-01